Pharma & Biotech Global Week in Review 8 May 09 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page:

Highlights this week included:

Mircera (Methoxy polyethylene glycol-epoetin beta) – US: Federal Circuit revises Amgen v ITC (Patently-O) (Patent Baristas) (ITC 337 Law Blog) (Hal Wegner) (Patent Docs)


Alicia Greenidge to step down as Director of IFPMA (Intellectual Property Watch)

Flu crisis could lead to compulsory licences (Managing Intellectual Property) (IP Watchdog)

Africa: Generics now face trouble in Africa (Spicy IP)

Brazil tightens rules on drug companies’ influence on physicians (Intellectual Property Watch)

Poland: Average consumer and advertising of pharmaceutical products (Class 46)

US: Plant varieties: District Court E D California ruling means twenty years after patent expired, Sun World has exclusive right to the subject matter: Sun Pacific Farming Co-op, Inc v Sun World Intern. (Property intangible)

US: Supreme Court rules 9-0 that CAFC has jurisdiction to review case remanded by district court to state court: Carlsbad Technology Inc v HIF Bio, Inc et al (Managing Intellectual Property) (Patently-O)

US: Anticipation by a laundry list of prophetic DNA sequences: In re Gleave (Holman’s Biotech IP Blog)

US: Reverse payment settlements and biotechnology (Holman’s Biotech IP Blog)

US: Biogen seeks review and correction of patent term adjustment calculation in respect of ‘polymer conjugates of interferon debta-1A and uses’: Biogen Idec Ma v Doll (Patent Docs)


Azilect (Rasagiline) – US: PTO awards 5 year patent term extension to one of Teva’s patents covering Azilect (SmartBrief)

Chantix (Varenicline) – India: Dr Reddy’s files post-grant opposition against Pfizer’s patent covering Varenicline (Patent Circle)

Cipralex (Escitalopram) – US: Israel refuses Lundbeck’s escitalopram SPC application due to previous registration of racemate Citalopram (The SPC Blog)

CitraNatal/Foltabs nutritional supplements – US: Warner Chilcott Co files patent infringement suits against Midlothian Labs and Mission Pharmacal over prenatal supplements (Patent Docs)

Doryx (Doxycycline) – US: Warner Chilcott files new lawsuit for infringement of Doryx patent against Mylan (SmartBrief) (GenericsWeb)

Famvir (Famciclovir) – US: Novartis denied jury trial in Famvir suit against Roxane Labs (Patent Docs)

Lyrica (Pregabalin) – US: Pfizer files patent infringement suits against Sun Pharma, Lupin, Wockhardt, Cobalt, Actavis, Sandoz, Teva and Alphapharm to block generic Lyrica (Generic Pharmaceuticals and Patentology) (Patent Docs)

Metrogel (Metronidazole) – US: Galderma drops patent suit against Tolmar over Metrogel (Patent Docs)

Mircera (Methoxy polyethylene glycol-epoetin beta) – US: Federal Circuit revises Amgen v ITC (Patently-O) (Patent Baristas) (ITC 337 Law Blog) (Hal Wegner) (Patent Docs)

Tarceva (Erlotinib) – India: Delhi Patent Office rejects OSI Pharma patent for polymorph B form of Erlotinib hydrochloride in pre-grant opposition filed by Cipla (Patent Circle)

Treximet (Sumatriptan, Naproxen) – US: Par drops GSK from Treximet suit (Patent Docs)

Triptorelin – Germany: Federal Patent Court finds Triptorelin pamoate not new product in comparison with Triptorelin acetate, so SPC application denied (The SPC Blog)



%d bloggers like this: